PALO ALTO, Calif., Dec. 2, 2013 /PRNewswire/ -- Nora Therapeutics announced today that CEO Jeffrey K. Tong, Ph.D., will present at the Oppenheimer 24th Annual Healthcare Conference. The conference will take place Dec. 10 - 11 at the Crowne Plaza Hotel in New York City.
Dr. Tong will be presenting on Tuesday, Dec. 10 at 11:30 a.m. (EST). Investors attending the conference who would like to meet with Nora should contact their Oppenheimer representative or the Company. For additional information on Nora, please visit the Company's website at www.noratherapeutics.com.
About Nora Therapeutics, Inc.
Nora Therapeutics, Inc., is a specialty biopharmaceutical company focused on developing therapeutics to address unmet clinical needs in reproductive medicine. Nora's lead compound, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100's mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information about Nora Therapeutics, visit www.noratherapeutics.com.
SOURCE Nora Therapeutics